S Wunsch1, R Krause1, T Valentin1, J Prattes1, O Janata2, A Lenger2, R Bellmann-Weiler3, G Weiss3, I Zollner-Schwetz4. 1. Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Austria. 2. Department of Hygiene and Infection Control, Danube Hospital, Vienna, Austria. 3. Department of Internal Medicine II (Infectious Disease, Immunology, Rheumatology, Pneumology), Medical University of Innsbruck, Austria. 4. Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Austria. Electronic address: ines.schwetz@medunigraz.at.
Abstract
Dalbavancin, a lipoglycopeptide with prolonged half-life approved for the treatment of acute bacterial skin and soft tissue infections, can be used for the treatment of infections caused by gram-positive bacteria requiring long term treatment such as endocarditis, prosthetic joint infections (PJI) or osteomyelitis. Clinical data are limited in these settings. OBJECTIVES: To evaluate indications, safety, tolerability and long-term outcomes of dalbavancin-treated patients. Patients and methods Our multicenter, retrospective study includes patients who received dalbavancin in Austria from September 2016 to March 2018. 90-day outcomes and tolerability were determined. RESULTS: A total of 101 patients were included in 3 centers (57% male, median age 65 years). The treated infections were PJI (31%), osteomyelitis (29%), endocarditis (25%) and acute bacterial skin and soft tissue infections (12%). Concomitant use of other antimicrobial substances was common (63%). The mean total cumulative dose of dalbavancin was 3,357mg (±2,283mg). Clinical success rate was 89%. Side effects occurred in 3/101 patients. CONCLUSION: In this real-life study dalbavancin was primarily used in off-label indications for treatment of PJI, osteomyelitis and endocarditis. Success rate was high (89%), tolerability and safety were excellent in this setting. Dalbavancin may therefore be used in these off-label indications as alternative treatment approach.
Dalbavancin, a lipoglycopeptide with prolonged half-life approved for the treatment of acute bacterial skin and soft tissue infections, can be used for the treatment of infections caused by gram-positive bacteria requiring long term treatment such as endocarditis, prosthetic joint infections (PJI) or osteomyelitis. Clinical data are limited in these settings. OBJECTIVES: To evaluate indications, safety, tolerability and long-term outcomes of dalbavancin-treated patients. Patients and methods Our multicenter, retrospective study includes patients who received dalbavancin in Austria from September 2016 to March 2018. 90-day outcomes and tolerability were determined. RESULTS: A total of 101 patients were included in 3 centers (57% male, median age 65 years). The treated infections were PJI (31%), osteomyelitis (29%), endocarditis (25%) and acute bacterial skin and soft tissue infections (12%). Concomitant use of other antimicrobial substances was common (63%). The mean total cumulative dose of dalbavancin was 3,357mg (±2,283mg). Clinical success rate was 89%. Side effects occurred in 3/101 patients. CONCLUSION: In this real-life study dalbavancin was primarily used in off-label indications for treatment of PJI, osteomyelitis and endocarditis. Success rate was high (89%), tolerability and safety were excellent in this setting. Dalbavancin may therefore be used in these off-label indications as alternative treatment approach.
Authors: Truc T Tran; Sara Gomez Villegas; Samuel L Aitken; Susan M Butler-Wu; Alex Soriano; Brian J Werth; Jose M Munita Journal: Antimicrob Agents Chemother Date: 2022-04-27 Impact factor: 5.938
Authors: Maria Arrieta-Loitegui; Jose Manuel Caro-Teller; Sara Ortiz-Pérez; Francisco López-Medrano; Rafael San Juan-Garrido; Jose Miguel Ferrari-Piquero Journal: Eur J Hosp Pharm Date: 2020-10-05
Authors: Jacqueline T Bork; Emily L Heil; Shanna Berry; Eurides Lopes; Rohini Davé; Bruce L Gilliam; Anthony Amoroso Journal: Infect Dis Ther Date: 2019-05-03